Boston, USA-based Albireo Pharma (Nasdaq: ALBO) - a spinoff of UK-based AstraZeneca (LSE: AZN) - is moving ahead with the regulatory process for odevixibat.
Albireo has submitted for marketing approval for the treatment of pruritus in people with progressive familial intrahepatic cholestasis (PFIC), a rare and serious disorder that causes progressive, life-threatening liver disease.
The US Food and Drug Administration has granted Priority Review designation to the firm’s submission and is expected to provide a decision by July 20, 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze